Quantum BioPharma Overview
Quantum BioPharma (QNTM) has a P/E ratio of -0.54, below the sector sector average of 33.83.
Get informed when a big investor buys or sells
+ Follow-0.54
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
Quantum BioPharma (QNTM) currently reports a P/E ratio of -0.54. That is below the sector sector average of 33.83. Use the charts on this page to explore Quantum BioPharma's P/E ratio history and peer comparisons.
Quantum BioPharma's P/E ratio of -0.54 is lower than the its sector sector average of 33.83. That is roughly 101.6% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
The P/E ratio is a valuation multiple that relates Quantum BioPharma's market price to a fundamental measure such as earnings, sales, or book value. At -0.54, QNTM can look expensive or cheap only in context — versus its own history, growth rate, and sector peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.
Start with the current P/E ratio of -0.54, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is 33.83. From there, open related valuation or income-statement pages for Quantum BioPharma, and consider following QNTM for alerts when major investors trade the stock.
